Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients
Kunal Mahajan, Director and Chief Interventional Cardiologist at Himachal Heart Institute, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Happy to share our study in the Journal of Clinical Lipidology.
In ACS patients treated with triple oral lipid-lowering therapy, lipoprotein(a) increased significantly after ACS, and higher baseline lipoprotein(a) predicted failure to achieve low-density lipoprotein cholesterol less than fifty milligrams per deciliter at one month.”
Title: Changes in Lipoprotein(a) and Their Association With LDL-C in ACS Patients Treated with Triple Oral Lipid-Lowering Therapy
Authors: Kunal Mahajan, Nitin Mahajan, Jai Bharat Sharma, Surender Himral, Tanuj Bhatia, Deep Dutta
Read the Full Article on Journal of Clinical Lipidology

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia